Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biosimilar Prescribing Decisions May Depend Upon Disease State

Executive Summary

Express Scripts’ Eichholz says clinicians may be less inclined to use a biosimilar in ‘life or death’ oncology indications compared to inflammatory diseases.


Related Content

Will Epoetin Biosimilar Serve As Non-Medical Switching Case Study?
Biosimilar Guidance Development Timelines Criticized By Docs And Patients
How Risky Is Pfizer’s Launch Of Its Remicade Biosimilar?
UnitedHealthcare Prefers Basaglar Biosimilar At Lantus' Expense
Rise Of The Biosimilar Formulary: CVS Excludes Lantus, Neupogen For 2017
Biosimilar Non-Medical Switching: Advocacy Groups, FDA Advisors Push For Action


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts